Delving into the Latest Updates on Brixun Pharmaceutical (Nantong) Co., Ltd. with Synapse

Overview

Tags

Nervous System Diseases

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Nervous System Diseases	1

Top 5 Drug Type	Count

Small molecule drug	1

Top 5 Target	Count

OX2R(Orexin receptor type 2)	1

Primary study objectives: Evaluate the safety and tolerability of BrP-01096 after single and multiple administrations in healthy subjects. Secondary study objectives: Evaluate the pharmacokinetic characteristics of BrP-01096 after single and multiple administrations in healthy subjects. Identify the metabolites of BrP-01096 in human plasma.

Start Date-

Sponsor / Collaborator

Brixun Pharmaceutical (Nantong) Co., Ltd.

[+1]

100 Clinical Results associated with Brixun Pharmaceutical (Nantong) Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Brixun Pharmaceutical (Nantong) Co., Ltd.

Login to view more data

100 Deals associated with Brixun Pharmaceutical (Nantong) Co., Ltd.

Login to view more data

100 Translational Medicine associated with Brixun Pharmaceutical (Nantong) Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

Login to view more data